# Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese

> **NCT01679028** · PHASE1 · COMPLETED · sponsor: **Tasly Pharmaceuticals, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** T89 Group A
- **DRUG:** Placebo Group A
- **DRUG:** Placebo Group B
- **DRUG:** T89 Group B
- **DRUG:** Placebo Group C
- **DRUG:** T89 Group C

## Key facts

- **NCT ID:** NCT01679028
- **Lead sponsor:** Tasly Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2012-10
- **Final completion:** 2013-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01679028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01679028, "Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01679028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*